S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Zai Lab (ZLAB) Stock Forecast, Price & News

+2.41 (+7.32%)
(As of 05/17/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
489,448 shs
Average Volume
778,939 shs
Market Capitalization
$3.46 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

Zai Lab logo

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$144.31 million
Book Value
$14.31 per share


Net Income
$-704.47 million
Net Margins
Pretax Margin




Free Float
Market Cap
$3.46 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.99 out of 5 stars

Medical Sector

604th out of 1,426 stocks

Pharmaceutical Preparations Industry

277th out of 680 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

Is Zai Lab a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab
or view top-rated stocks.

When is Zai Lab's next earnings date?

Zai Lab is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Zai Lab

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) announced its quarterly earnings results on Tuesday, March, 1st. The company reported ($2.24) EPS for the quarter, missing the consensus estimate of ($1.66) by $0.58. The business earned $44.17 million during the quarter, compared to analysts' expectations of $54.78 million. Zai Lab had a negative trailing twelve-month return on equity of 37.26% and a negative net margin of 324.08%.
View Zai Lab's earnings history

What guidance has Zai Lab issued on next quarter's earnings?

Zai Lab updated its first quarter earnings guidance on Tuesday, May, 10th. The company provided EPS guidance of ($0.86) for the period, compared to the consensus estimate of ($1.23). The company issued revenue guidance of $46.7 million, compared to the consensus revenue estimate of $45.72 million.

What price target have analysts set for ZLAB?

5 equities research analysts have issued 1-year target prices for Zai Lab's shares. Their forecasts range from $64.00 to $193.00. On average, they expect Zai Lab's share price to reach $117.50 in the next year. This suggests a possible upside of 232.4% from the stock's current price.
View analysts' price targets for Zai Lab
or view top-rated stocks among Wall Street analysts.

Who are Zai Lab's key executives?
Zai Lab's management team includes the following people:
  • Dr. Ying Du Ph.D., Founder, Chairperson & CEO (Age 56, Pay $1.38M)
  • Mr. Ki Chul Cho, Chief Financial Officer (Age 44, Pay $624.96k)
  • Mr. Frazor Titus Edmondson III, Chief Legal Officer & Corp. Sec. (Age 56, Pay $707.3k)
  • Dr. Alan Bart Sandler M.D., Pres & Head of Global Devel. in Oncology (Age 65, Pay $545k)
  • Ms. Ann Beasley, Chief Compliance Officer
  • Dr. Ning Xu M.D., Exec. VP & Head of Clinical Operations (Age 57)
  • Dr. Jonathan J. Wang M.B.A., MBA, Ph.D., Exec. VP & Head of Bus. Devel. (Age 40)
  • Dr. James Yan DABT, M.D., Ph.D., Chief Operating Officer of R&D (Age 58)
  • Dr. Harald Reinhart M.D., Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases (Age 70) (LinkedIn Profile)
  • Mr. Yi Liang M.B.A., M.D., Chief Commercial Officer & Pres of Greater China (Age 51)
What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by many different retail and institutional investors. Top institutional shareholders include Invesco Ltd. (8.57%), BlackRock Inc. (4.07%), Viking Global Investors LP (3.25%), Baillie Gifford & Co. (2.83%), Vanguard Group Inc. (2.34%) and Segantii Capital Management Ltd (2.34%). Company insiders that own Zai Lab stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends for Zai Lab

Which major investors are selling Zai Lab stock?

ZLAB stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Baillie Gifford & Co., Brilliance Asset Management Ltd., State Street Corp, Tree Line Advisors Hong Kong Ltd., JPMorgan Chase & Co., Group One Trading L.P., and Goldman Sachs Group Inc.. Company insiders that have sold Zai Lab company stock in the last year include Harald Reinhart, John D Diekman, Tao Fu, William Ki Chul Cho, William Lis, and Ying Du.
View insider buying and selling activity for Zai Lab
or view top insider-selling stocks.

Which major investors are buying Zai Lab stock?

ZLAB stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Invesco Ltd., Segantii Capital Management Ltd, Genesis Investment Management LLP, Woodline Partners LP, Zeal Asset Management Ltd, BlackRock Inc., and Bridgewater Associates LP.
View insider buying and selling activity for Zai Lab
or or view top insider-buying stocks.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $35.35.

How much money does Zai Lab make?

Zai Lab has a market capitalization of $3.46 billion and generates $144.31 million in revenue each year. The company earns $-704.47 million in net income (profit) each year or ($5.87) on an earnings per share basis.

How many employees does Zai Lab have?

Zai Lab employs 1,951 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is www.zailaboratory.com.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 862161632588, via email at [email protected], or via fax at 86-21-6163-2570.

This page was last updated on 5/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.